Quadria Capital Secures $1.07 Billion for Oversubscribed Healthcare Fund III

Quadria Capital, Asia’s leading healthcare-focused private equity firm, has successfully closed its Fund III at $1.07 billion - surpassing its initial $800 million target. The fund received overwhelming support, especially from investors across the Gulf Cooperation Council (GCC).

This latest milestone includes over $954 million in primary commitments and $114 million in co-investment capital. With an anticipated $300 million in additional co-investment opportunities during the fund’s deployment phase, total capital could reach approximately $1.3 billion.

Fund III is nearly 60% larger than Quadria’s previous $600 million fund launched in 2020, reinforcing the firm’s status as one of Asia’s most prominent healthcare private equity players. The fund aims to build a diverse portfolio of around 10 high-growth healthcare companies, offering both majority and significant minority stakes. It also provides unique co-investment opportunities for GCC investors seeking direct access to Asia's booming healthcare market.

Already nearly 40% deployed, Fund III has backed major players like Aragen Life Sciences, NephroPlus, and Maxivision, and two new investments in Southeast Asia are expected shortly.

To stay on top of what’s brewing in the healthcare space, visit :  https://www.marketsandata.com/industries/healthcare